A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs PRX 002 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms PASADENA
- Sponsors Roche
- 02 Jun 2017 Planned End Date changed from 20 Oct 2020 to 19 Oct 2020.
- 02 Jun 2017 Planned primary completion date changed from 30 Jul 2019 to 29 Jul 2019.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.